Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30770310,t1/,"Post-infusion, avalglucosidase alfa plasma concentrations declined monoexponentially (t1/2z∼1.0 h).","Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30770310/),h,2z∼1,97791,DB01272,Alglucosidase alfa
,30770310,t1/,"Post-infusion, avalglucosidase alfa plasma concentrations declined monoexponentially (t1/2z∼1.0 h).","Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30770310/),h,.0,97792,DB01272,Alglucosidase alfa
,21967859,Activity levels,Activity levels in the milk (245 nmol/ml.h) peaked at 2.5h after the end of the infusion; which was 2h later than in the plasma (80 μmol/ml.h).,First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967859/),[nM] / [h·ml],245,169209,DB01272,Alglucosidase alfa
,21967859,Activity levels,Activity levels in the milk (245 nmol/ml.h) peaked at 2.5h after the end of the infusion; which was 2h later than in the plasma (80 μmol/ml.h).,First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967859/),,80,169210,DB01272,Alglucosidase alfa
